Abstract PS8-06: A randomized, open-label phase III study comparing disitamab vedotin (an anti-HER2 monoclonal antibody-MMAE conjugate) with lapatinib plus capecitabine in patients with HER2-positive, advanced breast cancer with liver metastasis
Year: 2025
Type: conference-abstract
Source: Clinical Cancer Research
Authors: Jiayu Wang, Quchang Ouyang, Weimin Xie, Zhaofeng Niu, Qingyuan Zhang, Xi Yan, Yue'e Teng, Jianying Chang, Ying Cheng, Hongyan Xu, Jingfen Wang, Herui Yao, Zhuangqing Yang, Tao Sun, Zhongsheng Tong, Xinhong Wu, Yongsheng Wang, Enxiang Zhou, Xiangshun Kong, Xujuan Wang, De Zeng, Shanshan Gu, Dandan Gao, Zerui Qu, Chenran Han, Jianmin Fang, Binghe Xu
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4411286403